Diana Miguel

Diana Miguel

Auto-generated profile, based on publicly available information

Diana Miguel

Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, 1649-035 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2012 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
LULuís Uva
Luís Uva
DMDiana Miguel
Diana Miguel
CPCatarina Pinheiro
Catarina Pinheiro
JAJoana Antunes
Joana Antunes
DCDiogo Cruz
Diogo Cruz
PFPaulo Filipe
Paulo Filipe
Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1–3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient’s needs and his/her expectations, prescribing to each patient the most suitable vehicle.

25 July 2012 in Autoimmune Diseases
Verified
Journal Article
Open access
PDF file
LULuís Uva
Luís Uva
DMDiana Miguel
Diana Miguel
CPCatarina Pinheiro
Catarina Pinheiro
JFJoão Pedro Freitas
João Pedro Freitas
MGManuel Marques Gomes
Manuel Marques Gomes
PFPaulo Filipe
Paulo Filipe
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.